Measles, Mumps, and Rubella - Centers for Disease Control and ...

More documents

Recommendations

Info

48 MMWR May 22, 1998To prevent droplet transmission of the disease, respiratory isolation precautions forpersons with mumps should be maintained for 9 days after onset of symptoms (e.g.,parotitis). If exposed to mumps, health-care workers who lack acceptable evidence ofimmunity (Table 1) should be excluded from the health-care facility from the 12th dayafter the first exposure through the 26th day after the last exposure. Workers in whomthe disease develops should be excluded from work until 9 days after the onset ofsymptoms.References1. Bloch AB, Orenstein WA, Stetler HC, et al. Health impact of measles vaccination in the UnitedStates. Pediatrics 1985;76:524–32.2. Siegel M, Fuerst HT. Low birth weight and maternal virus diseases: a prospective study ofrubella, measles, mumps, chickenpox, and hepatitis. JAMA 1966;197:680–4.3. Jespersen CS, Littauer J, Sagild U. Measles as a cause of fetal defects. Acta Paediatr Scand1977;66:367–72.4. Atmar RL, Englund JA, Hammill H. Complications of measles during pregnancy. Clin InfectDis 1992;14:217–26.5. Eberhart-Phillips JE, Frederick PD, Baron RC, Mascola L. Measles in pregnancy: a descriptivestudy of 58 cases. Obstet Gynecol 1993;82:797–801.6. Markowitz LE, Chandler FW, Roldan EO, et al. Fatal measles pneumonia without rash in achild with AIDS. J Infect Dis 1988;158:480–3.7. CDC. Measles in HIV-infected children, United States. MMWR 1988;37:183–6.8. CDC. Measles surveillance report No.11, 1977–1981. September 1982; 6–89.9. CDC. Summary of notifiable diseases, United States–1993. MMWR 1993;42:67.10. CDC. Reported vaccine-preventable diseases—United States, 1993, and the Childhood ImmunizationInitiative. MMWR 1994;43:57–60.11. The National Vaccine Advisory Committee. The measles epidemic: the problems, barriers, andrecommendations. JAMA 1991;266:1547–52.12. Atkinson WL. Epidemiology and prevention of measles. Dermatol Clin 1995;13:553–9.13. CDC. Measles—United States, 1995. MMWR 1996;45:305–7.14. CDC. Status report on the Childhood Immunization Initiative: reported cases of selected vaccine-preventablediseases—United States, 1996. MMWR 1997;46:665–71.15. Pan American Health Organization. Measles elimination by the year 2000. EPI Newsletter 1994;16:1–2.16. Rota JS, Rota PA, Redd SC, Pattamadilok S, Bellini WJ. Genetic analysis of measles virusesisolated in the United States, 1995–1996. J Infect Dis 1998;177:204–8.17. Watson JC, Redd SC, Rhodes PH, Hadler SC. The interruption of transmission of indigenousmeasles in the United States during 1993. Pediatr Infect Dis J 1998;17:363–6.18. Lindegren ML, Fehrs LJ, Hadler SC, Hinman AR. Update: rubella and congenital rubella syndrome,1980–1990. Epidemiol Rev 1991;13:341–8.19. Peckham CS. Clinical and laboratory study of children exposed in utero to maternal rubella.Arch Dis Child 1972;47:571–7.20. CDC. Rubella and congenital rubella syndrome—United States, 1984–1985. MMWR 1986;35:129–35.21. Cochi SL, Edmonds LD, Dyer K, et al. Congenital rubella syndrome in the United States, 1970–1985: on the verge of elimination. Am J Epidemiol 1989;129:349–61.22. Mellinger AK, Cragan JD, Atkinson WL, et al. High incidence of congenital rubella syndromeafter a rubella outbreak. Pediatr Infect Dis J 1995;14:573–8.23. Dales LG, Chin J. Public health implications of rubella antibody levels in California. Am J PublicHealth 1982;72:167–72.24. Dales LG, Chin J. An outbreak of congenital rubella. West J Med 1981;135:266–70.25. Lamprecht C, Schauf V, Warren D, Nelson K, Northrop R, Christiansen M. An outbreak of congenitalrubella syndrome in Chicago. JAMA 1982;247:1129–33.26. Kaplan KM, Cochi SL, Edmonds LD, Zell ER, Preblud SR. A profile of mothers giving birth toinfants with congenital rubella syndrome: an assessment of risk factors. Am J Dis Child 1990;144:118–23.
Vol. 47 / No. RR-8 MMWR 4927. Lee SH, Ewert DP, Frederick PD, Mascola L. Resurgence of congenital rubella syndrome inthe 1990’s: report on missed opportunities and failed prevention policies among women ofchildbearing age. JAMA 1992;267:2616–20.28. Johnson CE, Kumar ML, Whitwell J, et al. Antibody persistence after primary measles-mumpsrubellavaccine and response to a second dose given at four to six vs. eleven to thirteen years.Pediatr Infect Dis J 1996;15:687–92.29. Falk WA, Buchan K, Dow M, et al. The epidemiology of mumps in Southern Alberta, 1980–1982.Am J Epidemiol 1989;130:736–49.30. Cooney MK, Fox JP, Hall CE. The Seattle Virus Watch. VI. Observations of infections with andillness due to parainfluenza, mumps, and respiratory syncytial viruses and mycoplasma pneumoniae.Am J Epidemiol 1971;94:467–72.31. Philip RN, Reinhard KR, Lackman DB. Observations on a mumps epidemic in a “virgin” population.Am J Hygiene 1959;69:91.32. CDC. Mumps outbreaks on university campuses—Illinois, Wisconsin, South Dakota. MMWR1987;36:496–8,504–5.33. Hersh BS, Fine PEM, Kent WK, et al. Mumps outbreak in a highly vaccinated population.J Pediatr 1991;119:187–93.34. CDC. Mumps surveillance, January 1977–December 1982. Atlanta, US Department of Healthand Human Services, US Public Health Service, 1984.35. Werner CA. Mumps orchitis and testicular atrophy: I. Occurrence. Ann Intern Med 1950;32:1066.36. McGuiness AC, Gall EA. Mumps at army camps in 1943. War Med 1944;5:95.37. Reed D, Brown G, Merrick R, Sever J, Feltz E. A mumps epidemic on St. George Island, Alaska.JAMA 1967;199:133–7.38. Russell RR, Donald JC. The neurological complications of mumps. Br Med J 1958;2:27.39. Bray PF. Mumps—a cause of hydrocephalus? Pediatrics 1972;49:446.40. Miller HG, Stanton JB, Gibbons JL. Para-infectious encephalomyelitis and related syndromes.Q J Med 1956;25:247.41. Azimi PH, Cramblett HG, Haynes RE. Mumps meningoencephalitis in children. JAMA 1969:207:509.42. Hall R, Richards H. Hearing loss due to mumps. Arch Dis Child 1987;62:189.43. Vuori M, Lahikainen EA, Peltonen T. Perceptive deafness in connection with mumps: a studyof 298 servicemen suffering with mumps. Acta Otolaryngol 1962;55:231.44. Westmore GA, Pickard BH, Stern H. Isolation of mumps virus from the inner ear after suddendeafness. Br Med J 1979;1:14.45. Siegel MS, Fuerst HT, Peress NS. Comparative fetal mortality in maternal virus diseases: aprospective study on rubella, measles, mumps, chickenpox, and hepatitis. N Engl J Med 1966;274:768–71.46. Siegel MS. Congenital malformations following chickenpox, measles, mumps and hepatitis:results of a cohort study. JAMA 1973;226:1521-4.47. Chaiken BP, Williams NM, Preblud SR, Parkin W, Altman R. The effect of a school entry lawon mumps activity in a school district. JAMA 1987;257(18): 2455–8.48. CDC. Mumps—United States, 1980–1983. MMWR 1983;32:545–7.49. CDC. Mumps—United States, 1985–1988. MMWR 1989;38:101–5.50. Van Loon FPL, Holmes SJ, Sirotkin BI, et al. Mumps surveillance—United States, 1988–1993.MMWR 1995;44(No. SS-3):1–14.51. Cochi SL, Preblud SR, Orenstein WA. Perspectives on the relative resurgence of mumps inthe United States. Am J Dis Child 1988;142:499–507.52. CDC. Measles prevention: recommendations of the Immunization Practices Advisory Committee(ACIP). MMWR 1989;38(No. S-9):1–18.53. American Academy of Pediatrics. Mumps. In: Peter G, ed. 1997 Red Book—report of the Committeeon Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics,1997:366–9.54. Watson JC, Pearson JA, Markowitz LE, et al. An evaluation of measles revaccination amongschool-entry-aged children. Pediatrics 1996;97:613–8.55. Markowitz LE, Preblud SR, Fine PE, Orenstein WA. Duration of live measles vaccine-inducedimmunity. Pediatr Infect Dis J 1990;9:101–10.
Page 1 and 2:
May 22, 1998 / Vol. 47 / No. RR-8TM
Page 3 and 4:
Vol. 47 / No. RR-8 MMWR iContentsIn
Page 5 and 6: Vol. 47 / No. RR-8 MMWR iiiAdvisory
Page 7 and 8: Vol. 47 / No. RR-8 MMWR vAdvisory C
Page 9 and 10: Vol. 47 / No. RR-8 MMWR 1Measles, M
Page 11 and 12: Vol. 47 / No. RR-8 MMWR 3greatest d
Page 13 and 14: Vol. 47 / No. RR-8 MMWR 5Rubella El
Page 15 and 16: Vol. 47 / No. RR-8 MMWR 7intermedia
Page 17 and 18: Vol. 47 / No. RR-8 MMWR 9Vaccine Sh
Page 19 and 20: TABLE 1. Acceptable presumptive evi
Page 21 and 22: Vol. 47 / No. RR-8 MMWR 13When meas
Page 23 and 24: Vol. 47 / No. RR-8 MMWR 15evidence
Page 25 and 26: Vol. 47 / No. RR-8 MMWR 17Women of
Page 27 and 28: Vol. 47 / No. RR-8 MMWR 194% among
Page 29 and 30: Vol. 47 / No. RR-8 MMWR 21SPECIAL C
Page 31 and 32: Vol. 47 / No. RR-8 MMWR 23protectio
Page 33 and 34: Vol. 47 / No. RR-8 MMWR 25Passively
Page 35 and 36: Vol. 47 / No. RR-8 MMWR 27are liste
Page 37 and 38: Vol. 47 / No. RR-8 MMWR 29In 1994,
Page 39 and 40: Vol. 47 / No. RR-8 MMWR 31women, th
Page 41 and 42: Vol. 47 / No. RR-8 MMWR 33observed
Page 43 and 44: Vol. 47 / No. RR-8 MMWR 35a contact
Page 45 and 46: Vol. 47 / No. RR-8 MMWR 37SteroidsS
Page 47 and 48: Vol. 47 / No. RR-8 MMWR 39• is no
Page 49 and 50: Vol. 47 / No. RR-8 MMWR 41Measles O
Page 51 and 52: Vol. 47 / No. RR-8 MMWR 43Cases mee
Page 53 and 54: Vol. 47 / No. RR-8 MMWR 45rubella-s
Page 55: Vol. 47 / No. RR-8 MMWR 47Laborator
Page 59 and 60: Vol. 47 / No. RR-8 MMWR 5181. Briss
Page 61 and 62: Vol. 47 / No. RR-8 MMWR 53130. CDC.
Page 63 and 64: Vol. 47 / No. RR-8 MMWR 55179. Amer
Page 65 and 66: Vol. 47 / No. RR-8 MMWR 57230. Amer
Page 67: MMWRThe Morbidity and Mortality Wee
show all

Measles, Mumps, and Rubella - Centers for Disease Control and ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?